Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

APF530

A controlled-release formulation of a biodegradable poly(ortho ester) polymer, encapsulating the indazole derivative granisetron, with antiemetic activity. Upon administration of APF530, the polymer slowly erodes and releases the active ingredient granisetron. As a selective serotonin receptor antagonist, granisetron competitively blocks the action of serotonin at 5-hydroxytryptamine3 (5-HT3) receptors, resulting in the suppression of nausea and vomiting over a sustained period of time.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	APF-530

APF530

Search NCI's Drug Dictionary